CCM
SLXP

Chilton Capital Management’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Chilton Capital Management’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-130
Closed -$11.7K – 352
2013
Q4 		$11.7K Sell
130
-90
-41% -$7.18K ﹤0.01% 319
2013
Q3 		$14.7K Hold
220
– – ﹤0.01% 310
2013
Q2 		$15K Buy
+220
New +$12.6K ﹤0.01% 316

Other funds holding SLXP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Chilton Capital Management's SLXP Position: Q1 2014 in Review

Chilton Capital Management sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q1 2014, closing a stake of 130 shares — an estimated $11.7K sold.

Chilton Capital Management first reported a position in SLXP in Q2 2013 and held it in 3 quarters. The position peaked at $15K in Q2 2013. 304 funds tracked by Wall St. Rank hold SLXP as of Q1 2014.

  • Chilton Capital Management reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q1 2014 after selling out during the quarter.
  • Chilton Capital Management sold 130 SALIX PHARMACEUTICALS LTD DEL shares in Q1 2014, an estimated $11.7K.
  • Chilton Capital Management first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q2 2013 and held it in 3 quarters.
  • Chilton Capital Management's SALIX PHARMACEUTICALS LTD DEL position peaked at $15K in Q2 2013.
  • 304 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q1 2014.

Based on Chilton Capital Management's 13F filing for Q1 2014, filed 12 May 2014.